These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 34503174)

  • 1. Paving the Way for Immunotherapy in Pediatric Acute Myeloid Leukemia: Current Knowledge and the Way Forward.
    Koedijk JB; van der Werf I; Calkoen FG; Nierkens S; Kaspers GJL; Zwaan CM; Heidenreich O
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia.
    Vadakekolathu J; Minden MD; Hood T; Church SE; Reeder S; Altmann H; Sullivan AH; Viboch EJ; Patel T; Ibrahimova N; Warren SE; Arruda A; Liang Y; Smith TH; Foulds GA; Bailey MD; Gowen-MacDonald J; Muth J; Schmitz M; Cesano A; Pockley AG; Valk PJM; Löwenberg B; Bornhäuser M; Tasian SK; Rettig MP; Davidson-Moncada JK; DiPersio JF; Rutella S
    Sci Transl Med; 2020 Jun; 12(546):. PubMed ID: 32493790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity.
    Lamble AJ; Lind EF
    Front Oncol; 2018; 8():213. PubMed ID: 29951373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in immunotherapy for pediatric acute myeloid leukemia.
    Bonifant CL; Velasquez MP; Gottschalk S
    Expert Opin Biol Ther; 2018 Jan; 18(1):51-63. PubMed ID: 28945115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redirecting the Immune Microenvironment in Acute Myeloid Leukemia.
    Sendker S; Reinhardt D; Niktoreh N
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing the immune system in acute myeloid leukaemia.
    Austin R; Smyth MJ; Lane SW
    Crit Rev Oncol Hematol; 2016 Jul; 103():62-77. PubMed ID: 27247119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myeloid leukaemia and the immune system: implications for immunotherapy.
    Barrett AJ
    Br J Haematol; 2020 Jan; 188(1):147-158. PubMed ID: 31782805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia.
    Anguille S; Van Tendeloo VF; Berneman ZN
    Leukemia; 2012 Oct; 26(10):2186-96. PubMed ID: 22652755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment.
    Isidori A; Salvestrini V; Ciciarello M; Loscocco F; Visani G; Parisi S; Lecciso M; Ocadlikova D; Rossi L; Gabucci E; Clissa C; Curti A
    Expert Rev Hematol; 2014 Dec; 7(6):807-18. PubMed ID: 25227702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?
    Rafelson WM; Reagan JL; Fast LD; Lim SH
    Leuk Lymphoma; 2017 Nov; 58(11):2523-2531. PubMed ID: 28351186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy.
    Mendez LM; Posey RR; Pandolfi PP
    Front Oncol; 2019; 9():1162. PubMed ID: 31781488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
    Acheampong DO; Adokoh CK; Asante DB; Asiamah EA; Barnie PA; Bonsu DOM; Kyei F
    Biomed Pharmacother; 2018 Jan; 97():225-232. PubMed ID: 29091870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Novel therapies for pediatric acute myeloid leukemia: building future strategies through incorporation of treatment currently used in adults].
    Moritake H
    Rinsho Ketsueki; 2020; 61(6):665-672. PubMed ID: 32624541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting the Immune Landscape of Acute Myeloid Leukemia.
    Davidson-Moncada J; Viboch E; Church SE; Warren SE; Rutella S
    Biomedicines; 2018 Nov; 6(4):. PubMed ID: 30477280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapeutic strategies for relapse control in acute myeloid leukemia.
    Martner A; Thorén FB; Aurelius J; Hellstrand K
    Blood Rev; 2013 Sep; 27(5):209-16. PubMed ID: 23871358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Role for Lipid Mediators in Acute Myeloid Leukemia.
    Loew A; Köhnke T; Rehbeil E; Pietzner A; Weylandt KH
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31100828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moving Myeloid Leukemia Drug Discovery Into the Third Dimension.
    Cartledge Wolf DM; Langhans SA
    Front Pediatr; 2019; 7():314. PubMed ID: 31417884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune receptor repertoires in pediatric and adult acute myeloid leukemia.
    Zhang J; Hu X; Wang J; Sahu AD; Cohen D; Song L; Ouyang Z; Fan J; Wang B; Fu J; Gu S; Sade-Feldman M; Hacohen N; Li W; Ying X; Li B; Liu XS
    Genome Med; 2019 Nov; 11(1):73. PubMed ID: 31771646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?
    Rashidi A; Walter RB
    Expert Rev Hematol; 2016; 9(4):335-50. PubMed ID: 26778118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Therapy.
    Lievense L; Aerts J; Hegmans J
    Adv Exp Med Biol; 2016; 893():59-90. PubMed ID: 26667339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.